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Understanding the NSAID related risk of vascular events
Harald E Vonkeman, Jacobus R B J Brouwers, Mart A F J van de Laar
Concern is growing about an increased risk of throm-
botic events (including myocardial infarction and
stroke) during the use of non-steroidal anti-
inflammatory drugs (NSAIDs), in particular the so
called selective cyclo-oxygenase-2 (COX 2) inhibitors.
Although clinical trials give conflicting results with
respect to the incidence of vascular events, increasing
evidence shows that a class effect might exist for selec-
tive COX 2 inhibitors. Even before the massive
introduction of selective COX 2 inhibitors, observa-
tional studies showed that the use of NSAIDs causes
congestive heart failure in elderly patients.1 2 Con-
versely, the discontinuation of NSAIDs has also been
associated with increased risk of myocardial infarction,
especially in the first several weeks after stopping
chronic NSAID treatment.3
Many different mechanisms could explain the
different effects of classic NSAIDs and selective COX 2
inhibitors in relation to thrombotic vascular events. In
this review we link biochemical facts concerning
NSAIDs and COX inhibitors with data from clinical
trials.
Key enzymes: COX 1 and COX 2
The key step in the synthesis of prostaglandins, the
transformation of arachidonic acid to prostaglandin
H2, is catalysed by two different isoenzymes—cyclo-
oxygenase-1 and cyclo-oxygenase-2.4 COX 1 is
expressed constitutively at variable concentrations and
regulates normal physiology, such as the maintenance
of gastric mucosal integrity, kidney function, and plate-
let aggregation. Conversely, COX 2 is usually undetect-
able in most tissues and is selectively expressed after
exposition to inflammatory mediators or trauma
(fig 1).
The hypothesis formed is that the adverse gastroin-
testinal effects of NSAIDs are attributable to the inhibi-
tion of COX 1 and that selective inhibition of COX 2
would yield effective but gastrointestinally safer drugs.
A number of pharmaceutical companies developed
and tested this hypothesis and several selective COX 2
inhibitors were subsequently marketed.
The COX 2 hypothesis does, however, have an
unexpected and dark side. Within the endovascular
lumen, COX 1 and COX 2 have an important role in
the interaction between platelets and endothelial cells
and in thrombogenesis.5 Activated platelets produce
COX 1 dependent thromboxane A2. Thromboxane A2
acts as a platelet agonist and vasoconstrictor, and its
effects can be considered as prothrombotic. Nearby
endothelial and smooth muscle cells produce COX 2
dependent prostaglandin I2 (prostacyclin), especially
after cell damage has occurred, as occurs in the forma-
tion of atherosclerotic plaques.6 Prostacyclin is a natu-
ral platelet inhibitor and has vasodilatory effects.
Prostacyclin thus modulates the interaction between
platelets and the endovascular wall, inhibiting throm-
bogenesis and atherosclerosis.7 Selective COX 2
inhibitors may, by their irreversible covalent binding,
strongly impair the synthesis of the antithrombotic
prostacyclin while lacking any antiplatelet effects, thus
tipping the scales of homoeostasis in favour of throm-
bogenesis and vasoconstriction. As shown previously
by our group and others, platelet function is inhibited
by non-selective NSAIDs but not by selective COX 2
inhibitors.8 9 These in vitro findings suggest that selec-
tive COX 2 inhibitors may increase the risk of vascular
events, including myocardial infarction and stroke,
especially in patients with pre-existing endothelial
damage or a history of thromboembolic events—that is,
elderly patients.
Using human whole blood assays, NSAIDs can be
assessed and ranked for their in vitro level of COX 2
selectivity.10 Some classic NSAIDs more or less equiva-
lently inhibit COX 1 and COX 2; others show some
COX 2 selectivity. Selective COX 2 inhibitors on the
other hand, have shown a 200-300-fold selectivity for
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COX 2 (fig 2). As their effect is temporary and revers-
ible, only continuous high dosage of classic NSAIDs
will considerably inhibit COX 1 and COX 2. For selec-
tive COX 2 inhibitors, conversely, because of
irreversible covalent binding, considerable inhibition
of COX 2 (but not COX 1) might also be expected
during intermittent use and at lower dosage. In inflam-
matory states like in synovitis this irreversible COX 2
binding would be advantageous because of massive
overexpression of COX 2. However, in the interaction
between platelets and the endovascular wall, no
continuous overabundant expression of COX 2 is to be
expected. One could surmise that under normal
circumstances, the use of classic NSAIDs would not
greatly influence the production of platelet COX 1
dependent thromboxane A2 or the concentrations of
endothelial COX 2 dependent prostacyclin, thus
retaining the endovascular prothrombotic and anti-
thrombotic balance. However, cell damage, atheroscle-
rotic plaques, and laminar shear forces selectively
upregulate the expression of COX 2 by endothelial
cells in an attempt to maintain homoeostasis.11 In clini-
cal syndromes of platelet activation, therefore, COX
inhibition by any NSAID, but especially by selective
COX 2 inhibitors, could be expected to upset the
thrombotic equilibrium, increasing the risk of cardio-
vascular events.
Clinical data on cardiovascular events
On 7 April 2005, Pfizer agreed to suspend the market-
ing and sale of valdecoxib (Bextra) in the United States
and European Union pending further discussions with
the US Food and Drug Administration on the drug’s
overall risk versus benefit profile.12 Previously, on 30
September 2004, Merck Sharp & Dohme removed its
selective COX 2 inhibitor rofecoxib (Vioxx) from the
market. The reason for this was a raised risk of cardio-
vascular events, especially myocardial infarctions. The
Vioxx gastrointestinal outcome research study
(VIGOR) had previously shown that rofecoxib,
compared with naproxen, has noticeably less serious
gastrointestinal side effects. The same study, however,
also showed that rofecoxib, compared with naproxen,
carried an increased risk for thrombotic cardiovascular
events. In the group taking 50 mg of rofecoxib, 45
events occurred compared with 19 in the group taking
1000 mg of naproxen (P < 0.002).13 Overall, there were
more serious side effects with rofecoxib than with
naproxen and the way in which the VIGOR data were
presented has elicited an “expression of concern” as
not all observed myocardial infarctions were reported,
apparently purposely, resulting in an understatement
of the difference in risk.14–16
Although many subsequent retrospective case-
control studies seemed to confirm this raised risk, it
was the prospectively randomised adenomatous polyp
prevention on Vioxx study (APPROVe) which defini-
tively showed an increased risk for cardiovascular
events, such as myocardial infarctions and stroke. In
the APPROVe study, 46 of 1287 (3.6%) participants
taking 25 mg of rofecoxib compared with 26 of 1299
(2.0%) taking placebo, had a confirmed thrombotic
event after 18 months (relative risk 1.92, 95%
confidence interval 1.19 to 3.11).17 Although the risk
was relatively low, at 1.50 per 100 patient years, this was
reason for the voluntary worldwide withdrawal of
rofecoxib.
These series of events have led to greater scrutiny
of the remaining selective COX 2 inhibitors and also of
the NSAID group as a whole. Soon after the
withdrawal of rofecoxib yet another selective COX 2
inhibitor—namely, celecoxib (Celebrex), came under
fire. In the adenoma prevention with celecoxib study
(APC), 2035 participants were randomised to either a
daily dose of 400 mg or 800 mg of celecoxib or
placebo. The study was designed to assess whether
(high dose) celecoxib can prevent colon polyps. It was
to finish in spring 2005 but was terminated early by the
National Institutes of Health. In the APC study, partici-
pants who took 400 mg of celecoxib seemed to have
2.3 (0.9 to 5.5) times as much risk of having a major
cardiovascular event, compared with participants who
took placebo. In those taking a daily dose of 800 mg of
celecoxib the risk was increased by 3.4 (1.4 to 7.8)-fold.
After an average of 33 months, there were seven
cardiovascular events in 679 subjects in the placebo
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group, 16 in 685 in the 400 mg group, and 23 in 671 in
the 800 mg group.18 However, in two other long term
follow-up celecoxib studies, the celecoxib long term
arthritis safety study (CLASS) and the prevention of
spontaneous adenomatous polyps study (PreSAP) pre-
liminary reports do not suggest an increased
cardiovascular risk.19
A meta-analysis on two trials in high risk patients,
who had recently undergone coronary artery bypass
graft surgery, showed a significantly greater cardiovas-
cular risk for the selective COX 2 inhibitor valdecoxib
(Bextra) (relative risk 3.08; 1.20 to 7.87).20 Likewise, in a
study after coronary artery bypass graft surgery in
which patients received intravenous parecoxib (Dynas-
tat), a pro-drug which is converted into valdecoxib, fol-
lowed by oral valdecoxib, patients receiving valdecoxib
showed an increased risk of myocardial infarction
compared with patients receiving placebo.21 For the
selective COX 2 inhibitor lumiracoxib (Prexige), no
significant increase in cardiovascular events was found
compared with non-selective NSAIDs. In the therapeu-
tic arthritis research and gastrointestinal events trial
(TARGET), 18 325 patients with osteoarthritis were
randomly treated with lumiracoxib, naproxen, or
ibuprofen for one year.22 Event rates were similar, and
the adjusted hazard ratio did not increase significantly
(hazard ratio 1.14, 0.78 to 1.66). But absence of
evidence is not evidence of absence, as in this trial
patients with a high risk for cardiovascular events were
excluded and the number of events was quite low.
Recently, Merck Sharp and Dohme discussed
cardiovascular safety for the selective COX 2 inhibitor
etoricoxib (Arcoxia) in their new drug application
briefing. An increase of cardiovascular events was seen
for etoricoxib, compared with placebo or non-selective
NSAIDs. Furthermore, the marginal gastrointestinal
advantage of etoricoxib compared with naproxen was
entirely lost in users of low dose aspirin.23 However, the
original publications should be awaited before these
results can be taken into consideration.
To confuse matters, preliminary results from the
three year ongoing placebo controlled Alzheimer’s
disease anti-inflammatory prevention trial (ADAPT)
also suggested an increased cardiovascular risk for the
classic non-selective NSAID naproxen.24 In the ADAPT
trial, 2500 elderly patients had been taking 400 mg of
naproxen, 400 mg of celecoxib, or placebo from 2001
onwards to test the hypothesis that NSAIDs might
protect against the onset of Alzheimer’s disease in
those at risk. The National Institutes of Health recently
terminated this study early, after finding that those
taking naproxen had a 50% increase in cardiovascular
events compared with placebo.
Surprisingly, no increase was seen in those taking
celecoxib.24 This is however consistent with results from
a large case-control study in over 8000 patients taking
selective COX 2 inhibitors, that showed that patients
using rofecoxib were more likely to have a myocardial
infarction than those that took celecoxib (odds ratio
2.72; 1.24 to 5.95).25 These findings were confirmed in
another very large nested case-control study. In
2 302 029 person years of follow-up, 8143 cases of
acute myocardial infarction and sudden cardiac death
occurred. Rofecoxib increased the risk compared with
celecoxib, and naproxen use did not offer any
protection.26 Also, in a case-control study with 10 280
cases of first time admission to hospital for myocardial
infarction and 102 797 population controls, risk for
myocardial infarction was highest in users of rofecoxib,
but was also raised in other selective and non-selective
NSAID users, compared with non-users.27
Conclusion
A significant increase in risk of cardiovascular events in
NSAID users has been found in clinical trials and
observational studies, especially in patients taking
selective COX 2 inhibitors. Two selective COX 2
inhibitors have subsequently been taken off the
market, but others are still available to doctors and
patients. On the basis of the hypothesis outlined above,
in at-risk patients one may infer a mechanism of pros-
tanoid dependent conservation of arterial blood flow
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due to COX 2 upregulation. Selective COX 2
inhibition, because of its sparing of COX 1 and
irreversible binding of COX 2, can be expected to
upset this homoeostasis, increasing the risk for cardio-
vascular events. When prescribing NSAIDs, and
especially selective COX 2 inhibitors, doctors should
carefully weigh gastrointestinal harm with cardiovascu-
lar harm. Patients at risk for cardiovascular events
should not be treated with selective COX 2 inhibitors.
We thank Dr Peter C Gøtzsche for reading and reviewing the
manuscript.
Contributors: All authors researched and wrote this article.
HEV is guarantor.
Funding: None.
Competing interests: None declared.
1 Heerdink ER, Leufkens HG, Herings RM, Ottenvanger JP, Stricker BH,
Bakker A. NSAIDs associated with increased risk of congestive heart fail-
ure in elderly patients taking diuretics.Arch Intern Med 1998;158:1108-12.
2 Page J, Henry D. Consumption of NSAIDs and the development of con-
gestive heart failure in elderly patients: an underrecognized public health
problem. Arch Intern Med 2000;160:777-84.
3 Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR.
Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk
of acute myocardial infarction. Arch Intern Med 2004;164:2472-6.
4 Tanaka Y, Ward SL, Smith WL. Immunohistochemical and kinetic
evidence for two different prostaglandin H-prostaglandin E isomerases
in sheep vesicular gland microsomes. J Biol Chem 1987;262:1374-81.
5 FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroi-
dal anti-inflammatory drugs and coxibs: clinical considerations. Am J
Cardiol 2002;89(suppl):D26-32.
6 Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented
expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J
Pathol 1999;155:1281-91.
7 Fitzgerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin
biosynthesis in patients with severe atherosclerosis and platelet activation.
N Engl J Med 1984;310:1065-8.
8 Knijff-Dutmer EAJ, Kalsbeek-Batenburg EM, Koerts J, van de Laar MAFJ.
Platelet function is inhibited by non-selective non steroidal anti-
inflammatory drugs but not by cox-2 selective inhibitors in patients with
rheumatoid arthritis. Rheumatol 2004;41:458-61.
9 Knijff-Dutmer EAJ, Martens A, van de Laar MAFJ. Effects of nabumetone
compared with naproxen on platelet aggregation in patients with
rheumatoid arthritis. Ann Rheum Dis 1999;58:257-9.
10 FitzGerald GA, Patrono C. The coxibs, selective inhibitors of
cyclooxygenase-2. N Engl J Med 2001;345:433-42.
11 Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular
endothelial genes differentially responsive to fluid mechanical stimuli:
cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell
nitric oxide synthase are selectively up-regulated by steady laminar shear
stress. Proc Natl Acad Sci USA 1996;93:10417-22.
12 Food and Drug Administration. FDA announces series of changes to the
class of marketed non-steroidal anti-inflammatory drugs (NSAIDs).
Rockville, MD: FDA, 2005. www.fda.gov/bbs/topics/news/2005/
NEW01171.html (accessed 29 Mar 2006).
13 Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et
al. Comparison of upper gastrointestinal toxicity of rofecoxib and
naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med 2000;343:1520-8.
14 Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events
associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
15 Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of
cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet
2004;364:2021-9.
16 Curfman GD, Morrissey S, Drazen JM. Expression of concern:
Bombardier et al., “comparison of upper gastrointestinal toxicity of
rofecoxib and naproxen in patients with rheumatoid arthritis,” N Engl J
Med 2000;343:1520-8. N Engl J Med 2005;353:2813-4.
17 Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K,
et al. Cardiovascular events associated with rofecoxib in a colorectal
adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
18 Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al.
Cardiovascular risk associated with celecoxib in a clinical trial for
colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
19 Food and Drug Administration. FDA alert for practitioners: celecoxib
(marketed as Celebrex). Rockville, MD: FDA, 2005. www.fda.gov/cder/
drug/infopage/celebrex/celebrex-hcp.htm (accessed 29 Mar 2006).
20 Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, et al.
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and val-
decoxib in patients undergoing coronary artery bypass surgery. J Thorac
Cardiovasc Surg 2003;125:1481-92.
21 Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardio-
vascular risk. Circulation 2005;111:249.
22 Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW,
Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and
ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal
Event Trial (TARGET), cardiovascular outcomes: randomized controlled
trial. Lancet 2004;364:675-84.
23 Food and Drug Administration. Briefing package for NDA 21-389 etori-
coxib. Rockville, MD: FDA, 2005. www.fda.gov/ohrms/dockets/ac/05/
briefing/2005-4090B1_31_AA-FDA-Tab-T.pdf (accessed 29 Mar 2006).
24 National Institutes of Health. Use of non-steroidal anti-inflammatory
drugs suspended in large Alzheimer’s disease prevention trial. Bethesda,
MD:NIH, 2004. www.nih.gov/news/pr/dec2004/od-20.htm (accessed 29
Mar 2006).
25 Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, et al.
Patients exposed to rofecoxib and celecoxib have different odds of non-
fatal myocardial infarction. Ann Intern Med 2005;142:157-64.
26 Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk
of acute myocardial infarction and sudden cardiac death in patients treated
with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-
inflammatory drugs: nested case-control study. Lancet 2005;365: 475-81.
27 Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, et
al. Risk of hospitalization for myocardial infarction among users of
rofecoxib, celecoxib, and other NSAIDs. A population-based case-control
study. Arch Intern Med 2005;165:978-84.
(Accepted 8 February 2006)
Dr No
As doctors, we are enormously privileged to hear reminiscences
from our patients, which are especially appealing when they do
not concern their illness. With the emerging news of a “new”
James Bond to appear in the film Casino Royale, I was reminded
of a story told to me by a patient while I was a house surgeon at
Charing Cross Hospital in the early 1960s.
At that time, James Bond had appeared only as a literary
character and was not yet well known, but the book Dr No had
just been published and generated a huge following for the
novels of Ian Fleming. I had just read the book, and I noticed that
my patient had a copy on his bedside locker. He was anxious to
show me the book, and, on opening it, I saw the flyleaf had a
handwritten message: “To a true British patriot,” which was signed
“Ian Fleming.”
Understandably I asked him to explain the origin of this reference.
The patient had been the head waiter at a well known restaurant
in Piccadilly during the war years of 1939-45. One lunch time one
of his diners came to him and said that at the table next to him
were three men speaking German, and some of the words that he
could understand related to military events. In the tension of those
days he felt that someone should be alerted. My patient (who could
not understand German) agreed, and so he decided to call the
police. They asked that they could be seated close to the table in
question and for him to treat them as ordinary clients. They arrived
soon after, and he did as requested.
Some time later they seemed to have heard enough and arrested
the three men (in a gentlemanly way so as to not upset the other
diners).
My patient felt gratified that he had acted correctly until a few
days later, when he learnt that two of the men were German
officers who had been captured and the third was Ian Fleming, who
was not yet a successful writer but who was working in Naval
Intelligence at the War Office. His method of obtaining
information from prisoners of sufficient rank was to entertain them
well with a good meal and suitable wines.
The “patriotic” act was therefore somewhat diminished, since
events did not run their expected course.
Obviously Ian Fleming remembered the event well, and later he
became a regular client at the restaurant. On the publication of
Dr No, he took the opportunity of sending a copy, suitably
inscribed, to my patient as a friendly reminder of that occasion.
John C Nicholls retired general surgeon, Berkhamsted
(John.nicholls5@virgin.net)
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